On May 21, the U.S. Senate’s Permanent Subcommittee on Investigations held a crucial hearing titled "The Corruption of ...

This news roundup covers significant developments in the health industry, including France's Carmat filing for insolvency, ...

Astonishing claims have emerged from recent studies suggesting a chilling surge in cancer rates, particularly among women, reportedly linked to climate change. However, the narrative being pushed by ...

The most read stories this past month detailed the passing of Dimitrios Karmpaliotis and news on Evoque and COVID-19.

The trial readout comes at a time of turbulence in the vaccine sector after RFK Jr replaced every member of the ACIP panel.

Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial.   In a Phase 3 study, the ...

The mRNA drug developer said it will begin discussing approval with the FDA, which has adopted stricter vaccine review standards.

An influenza vaccine candidate from Moderna showed promising results in a late-stage trial, bringing the drug maker one step ...

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

Moderna's mRNA flu vaccine showed 26.6% better efficacy than a standard flu shot in adults 50 and older during a global Phase ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

The latest phase 3 win is a boost for Moderna’s attempts to create a flu/COVID combination vaccine. The company withdrew a filing for FDA approval for its combo candidate last month while it waited ...